Storia in 6 fonti

Roche snags rights to South Korean obesity treatment

Roche subsidiary secures global rights to manufacture South Korean obesity treatment.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

swissinfo.chStai leggendo2 g fa

Roche snags rights to South Korean obesity treatment

Roche subsidiary secures global rights to manufacture South Korean obesity treatment.

originale

Timeline cronologica

lunedì 24 agosto 2026·biopharmadive.com
Roche commits to lean-mass preservation with Hanmi obesity deal
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.
lunedì 24 agosto 2026·morningstar.com
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy

biopharmadive.com

3 g fa

Roche commits to lean-mass preservation with Hanmi obesity deal

For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.

Leggi questa versione → originale

koreatimes.co.kr3 g fa

Hanmi Pharm signs $2.3 bil. licensing deal with Roche's Genentech for obesity drug candidate - The Korea Times

Hanmi Pharm, a Korean pharmaceutical company, said Monday it has signed a 3.2 trillion-won ($2.3 billion) licensing deal with Genentech, a U.S.-bas...

Leggi questa versione → originale

endpoints.news2 g fa

Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset

Roche licenses Hanmi Pharm's non-incretin obesity drug HM17321 in a deal worth up to $2.3B, including $190M upfront.

Leggi questa versione → originale

morningstar.com3 g fa

Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy

Leggi questa versione → originale

koreaherald.com3 g fa

Hanmi signs record $2.3b obesity drug deal with Genentech

Hanmi Pharmaceutical said Monday it has inked an exclusive licensing agreement with Genentech for its obesity drug candidate HM17321 in a deal that could be wor

Leggi questa versione → originale

lunedì 24 agosto 2026·

koreaherald.com

Hanmi signs record $2.3b obesity drug deal with Genentech

Hanmi Pharmaceutical said Monday it has inked an exclusive licensing agreement with Genentech for its obesity drug candidate HM17321 in a deal that could be wor

lunedì 24 agosto 2026·

koreatimes.co.kr

Hanmi Pharm signs $2.3 bil. licensing deal with Roche's Genentech for obesity drug candidate - The Korea Times

Hanmi Pharm, a Korean pharmaceutical company, said Monday it has signed a 3.2 trillion-won ($2.3 billion) licensing deal with Genentech, a U.S.-bas...

lunedì 24 agosto 2026·

endpoints.news

Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset

Roche licenses Hanmi Pharm's non-incretin obesity drug HM17321 in a deal worth up to $2.3B, including $190M upfront.

lunedì 24 agosto 2026·

swissinfo.ch

Roche snags rights to South Korean obesity treatment

Roche subsidiary secures global rights to manufacture South Korean obesity treatment.